Remote Monitoring and Wearables Are Reshaping How Doctors Track Inflammatory Bowel Disease
A new review explores how remote monitoring, at-home biomarker tests, and wearables could predict IBD flares and expand access to quality care.
Summary
Remote patient monitoring (RPM) has grown rapidly since the COVID-19 pandemic, and this review examines how it is now being applied to inflammatory bowel disease (IBD). RPM uses tools that collect biometric, behavioral, and biochemical data outside the clinic. It is already established in cardiology, endocrinology, and psychiatry. In IBD, emerging approaches include point-of-care testing for standard biomarkers, new biomarkers drawn from sources such as mucus and sweat, and passive physiologic monitoring meant to predict and prevent relapses. The authors review the broader chronic disease literature, outline early IBD applications, and discuss the barriers that still limit wider adoption. Based on the abstract alone, this is a narrative overview rather than a trial, so it points to promise and direction rather than proven outcomes.
Detailed Summary
Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is a lifelong condition marked by unpredictable flares. Traditional care depends on periodic clinic visits, labs, and endoscopy, which can miss early signs of relapse. Remote patient monitoring (RPM) offers a way to follow patients continuously between visits.
This article from Said and Hirten at Mount Sinai is a review. It looks at the existing literature on RPM across chronic diseases, then focuses on emerging uses in IBD. RPM spans tools that gather biometric, behavioral, and biochemical data outside traditional clinical settings, and it has been adopted in fields such as cardiology, endocrinology, and psychiatry, where real-time data supports timely management.
According to the abstract, IBD-focused innovation falls into three areas. First, point-of-care testing brings conventional biomarkers closer to the patient. Second, researchers are developing novel biomarkers from other biospecimens, including mucus and sweat. Third, passive physiologic monitoring, such as data from wearable devices, aims to predict and prevent disease relapses before symptoms escalate.
The implications are potentially significant: earlier detection of flares, improved access for patients far from specialty centers, and more personalized, proactive care. The review also acknowledges key barriers to broader implementation, though the abstract does not specify them.
Caveats are important. Only the abstract was available, so details on specific studies, effect sizes, and the named barriers cannot be assessed. As a narrative review, it does not provide new trial data, and the clinical benefit of many IBD-specific RPM tools still needs validation in larger prospective studies.
Key Findings
- RPM has become a valuable complement to in-person care, particularly since the COVID-19 pandemic.
- RPM is already integrated in cardiology, endocrinology, and psychiatry, supporting timely management of chronic conditions.
- IBD care is adopting point-of-care testing for conventional biomarkers to bring monitoring closer to patients.
- Novel biomarkers from biospecimens such as mucus and sweat are under development for IBD.
- Passive physiologic monitoring aims to predict and prevent IBD relapses; barriers still limit broad implementation.
Methodology
This is a narrative review that examines the literature on remote patient monitoring across chronic diseases and its emerging applications in IBD. The abstract does not describe a systematic search strategy, inclusion criteria, or quantitative synthesis.
Study Limitations
Only the abstract was available, so specific studies, outcomes, and the barriers discussed could not be evaluated. As a narrative review, it carries risk of selection bias and offers no new primary data. Many IBD-specific RPM technologies, especially sweat and mucus biomarkers and passive monitoring for relapse prediction, appear to be early-stage.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
